(688117)"CHENGDU SHENG NUO BIOTEC CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 688117 · · 13 pages · Chinese
Summary by 6ix AI
The report indicates that the company has experienced significant growth in revenue compared to the previous year, primarily due to increased overseas sales of raw materials. The report also highlights ongoing legal issues involving the company's subsidiary, which may impact future performance.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Cheng Du Sheng Nuo Biotec Co., Ltd. on 6ix
Earlier from Cheng Du Sheng Nuo Biotec
- (688117)"CHENGDU SHENG NUO BIOTEC CO., LTD."Announcement on Voluntary Disclosure of Receipt of Drug Registration Certificate for Terlipressin Injection
- (688117)"CHENGDU SHENG NUO BIOTEC CO., LTD."Announcement on Voluntary Disclosure of Receipt of the Written Confirmation for Active Substances Exported to EU by Wholly-owned Subsidiary
- (688117)"CHENGDU SHENG NUO BIOTEC CO., LTD."Announcement on Receipt of Indictment by the Wholly-owned Subsidiary and the Actual Controller
- (688117)"CHENGDU SHENG NUO BIOTEC CO., LTD."Announcement on Progress of Shareholding Increase by Senior Executive
- CHENGDU SHENG NUO BIOTEC CO., LTD.: Announcement on Voluntary Disclosure of Wholly-owned Subsidiary Obtaining the Drug Manufacturing License for New API Varieties and Passing the GMP Compliance Inspection
Later from Cheng Du Sheng Nuo Biotec
All Cheng Du Sheng Nuo Biotec news releasesFollow Cheng Du Sheng Nuo Biotec into a list and get an email when it puts out news.
Follow Cheng Du Sheng Nuo Biotec